What Is Angina? Symptoms, Causes, Diagnosis, Treatment, and Prevention
Fortrea Establishes Industry Partnership With Veeva And Advarra To Streamline Patient And Site Clinical Trial Experience
DURHAM, N.C., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today announced an industry partnership with founding members Veeva Systems Inc., a leading provider of industry cloud solutions for the global life sciences industry, and Advarra, a leading provider of clinical research technology for clinical research investigator sites and sponsors, to deliver an integrated patient- and site-centric solution that streamlines the clinical trial experience.
In an industry faced with complex challenges to clinical trial execution, Fortrea is establishing an alliance of industry partners—beginning with founding members, Veeva and Advarra—to tackle some of these challenges head-on. Many sites are burdened by administrative operations that have multiple, complex technologies with limited interoperability. This impacts their ability to focus on what matters most—the patients—and improving their recruitment and experience participating in clinical studies.
Fortrea, Veeva and Advarra are partnering to offer a seamless, unified technology solution that integrates best-in-class technologies and leverages Fortrea's process expertise. This will help ease the administrative burden for patients and sites and increase the accessibility of clinical trials for the public.
"We heard from our Site Advisory Board that the multitude of technologies used on a study is one of their greatest challenges," said Fortrea Chief Operating Officer and President of Clinical Services Mark Morais. "Working with industry-leading partners and founding members, Veeva and Advarra, we're taking action to remove complexities so we can address the pain points of sites and patients and make a difference. We are leveraging our unique vantage point in the industry that enables us to layer our expertise over the tech and data ecosystems from best-in-class partners—adding to our alliance as we go—to dramatically simplify the experience for patients, sites and sponsors."
For sites, the partnership is set to deliver:
For patients, the solution is being designed to offer:
"Veeva is helping to advance clinical trials with connected applications that reduce the burden of participating for patients, streamline execution for research sites and increase transparency for sponsors," said Jim Reilly, vice president, Veeva Development Cloud Strategy. "Extending our partnership with Fortrea to deliver Veeva Clinical Platform applications will meet the unique needs of patients, sites and sponsors while significantly improving study data quality and collaboration with sites."
"Advarra's mission is to break the silos that impede clinical research, so we are excited to provide our Longboat solution and IRB services as part of this innovative and collaborative partnership aimed at reducing site and patient burden," said Elisa Cascade, chief product officer at Advarra. "By leveraging our Longboat solution, Fortrea will deliver a reimagined clinical research experience that will improve both protocol compliance and site and patient engagement throughout the clinical trial process."
Learn more about how Fortrea is driving healthcare innovation throughout the world at Fortrea.Com. For more information on the technology platforms, visit Veeva Clinical Platform and Advarra Longboat.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of about 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.Com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.
Fortrea Contacts:Fortrea Media: Galen Wilson – 703-298-0802, media@fortrea.ComFortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.Com
Medidata Secures Top Honors In Everest Group's Decentralized Clinical Trial Platforms PEAK Matrix® Assessment
NEW YORKMedidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, has again been recognized as a Leader in Everest Group's recently published "Decentralized Clinical Trials Platforms PEAK Matrix® Assessment 2023." Medidata was the only provider to receive a "Star Performer" designation for the second consecutive year, reflecting its continued innovation and leadership.
The report evaluated the vision, capabilities, and market impact of 22 decentralized clinical trial (DCT) platform providers based on relevant customer case studies, revenue, key offerings, and their latest progress.
"Medidata's unified platform harnesses DCT technology to optimize patient, site, and sponsor experiences, delivering more inclusive studies," said Anthony Costello, chief executive officer, Medidata Patient Cloud, Medidata. "We're honored to be recognized as a Leader by Everest Group in DCT platform providers, demonstrating our extensive experience and leadership in a rapidly evolving industry."
In this year's assessment, Medidata distinguished itself through substantial investments in next-generation and patient-centric DCT technologies within Medidata AI and Medidata Patient Cloud, such as the Medidata Diversity Program, the myMedidata application, and Medidata Rave Companion. As a Leader, Medidata was also recognized for its domain expertise and user experience for patients and sites, as well as its global capabilities to orchestrate DCTs.
"Medidata offers an end-to-end, comprehensive DCT platform, covering ePRO/eCOA, eConsent, televisits, patient recruitment, and engagement. With deep domain expertise, strategic partnerships, and industry experience, Medidata has achieved widespread adoption of its solutions," said Nisarg Shah, practice director at Everest Group. "Its investments in building a unified experience for sites and patients have positioned Medidata as a Leader and a Star Performer in the Decentralized Clinical Trial Platforms PEAK Matrix Assessment 2023."
Medidata's platform has powered nearly 1,700 DCTs and over 1.1 million patients across disease areas, countries, languages, and clinical trial phases. With this technology, Medidata supports patient participation in the right trial at the right time, from anywhere and with easier, faster, and better results.
About Medidata Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. With over 20 years of groundbreaking technological innovation across more than 30,000 trials and 9 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,100+ customers trust Medidata's seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. The company is a wholly owned subsidiary of Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization. Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.Medidata.Com and follow us @Medidata.
About Dassault Systèmes Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients, and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.Com
© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries.
View source version on businesswire.Com: https://www.Businesswire.Com/news/home/20240110694798/en/
Medidata PR Medidata.PR@3ds.Com
Analyst Relations Medidata.AR@3ds.Com
© Business Wire, Inc.
Disclaimer:This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact person/entity mentioned in the text of the press release.
Labcorp And Hawthorne Effect Collaborate To Bring Clinical Trials Directly To Patients And Investigators In Local Communities
Collaboration Aims to Improve Patient Experience, Accessibility and Efficiency in Decentralized Clinical Trials
BURLINGTON, N.C. And LAFAYETTE, Calif., Jan. 10, 2024 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, and Hawthorne Effect, Inc., a complete clinical trials solution integrating technology, are pleased to announce a strategic collaboration to advance decentralized clinical trial capabilities for pharma, biotech and medical device sponsors seeking to increase patient diversity and inclusion, decrease site burden, and accelerate enrollment and clinical study timelines.
On Jan. 10, Labcorp and Hawthorne Effect announced a collaboration to bring clinical trials directly to patients and investigators in local communities.
Through the collaboration, Labcorp and Hawthorne Effect aim to combine their services and create new, differentiated service offerings to support decentralized clinical trials. Hawthorne Effect's comprehensive digital platform allows complex study visits and clinical data collection to be conducted seamlessly in the patient home or community and has been demonstrated to increase diverse patient participation, improve quality, completeness and timeliness of trial data, and accelerate trial timelines.
"At Labcorp, we are committed to making life-saving clinical trials more accessible, diverse and inclusive to all communities," said Jonathan DiVincenzo, Labcorp's President of Central Laboratories and International. "Through this collaboration, we look forward to combining Labcorp's global laboratory network and logistics capabilities with Hawthorne Effect's digital platform to advance our decentralized clinical trial capabilities, increase clinical trial accessibility and diversity, and bring greater value to patients, their physicians and our sponsors."
"The combined expertise of both Labcorp and Hawthorne Effect will allow clinical trials to operate more efficiently with greater patient access and higher levels of compliance, resulting in timeline acceleration for customers," said Jodi Akin, Founder, Hawthorne Effect. "These advancements highlight our shared commitment to improving health across the globe."
Story continues
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.Labcorp.Com.
About Hawthorne Effect
Hawthorne Effect is a complete clinical trials solution integrating technology and people to transform the clinical trials industry. Its technology-enabled platform and distributed network of certified medical professionals, Hawthorne Heroes, enable patients and clinicians to participate in trials within their trusted community. Its solution accelerates clinical research and generates evidence that makes clinical trials accessible and convenient while delivering meaningful and high-quality clinical assessments. Since launching in 2015, Hawthorne Effect has helped complete 76 trials and worked with industry leaders within medtech, biopharma, retail health and healthcare systems. Learn more about Hawthorne Effect by visiting https://hawthorne-effect.Com/.
Labcorp Logo (PRNewsfoto/Labcorp)
Cision
View original content to download multimedia:https://www.Prnewswire.Com/news-releases/labcorp-and-hawthorne-effect-collaborate-to-bring-clinical-trials-directly-to-patients-and-investigators-in-local-communities-302030944.Html
SOURCE Laboratory Corporation of America Holdings
Comments
Post a Comment